ACTU Stock Forecast & Price Target

Actuate Therapeutics is expected to have a competitive advantage in the biopharmaceutical industry with its promising drug elraglusib, which has demonstrated a positive risk-benefit balance in a Phase 2 study for the treatment of metastatic pancreatic ductal adenocarcinoma. The company has received FDA clearance for a Phase 1/2 study of the oral formulation, which has >95% bioavailability and could achieve targeted drug exposure with only 1-2 tablets taken daily. The potential for Conditional Marketing Authorization in the EU and a planned global Phase 3 registrational study add to the potential commercial success of elraglusib, supporting a Buy rating and a 12-month price target of $15.

Actuate Therapeutics is expanding the evaluation of its potential blockbuster drug elraglusib, with upcoming regulatory meetings to finalize the development pathway of elraglusib for the treatment of metastatic pancreatic ductal adenocarcinoma. While the company's Phase 2 study showed positive results and a potential for conditional approval, the safety profile of the IV formulation may be a concern in a highly competitive treatment landscape. With expanding into pediatric oncology, Actuate may have a pathway for accelerated approval, but the niche market may limit potential revenue opportunities, leading to a negative outlook for the stock.